Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A

By: News Direct
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Incannex Healthcare Ltd (ASX:IHL, NASDAQ: IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics and the safety of the company’s anti-inflammatory drug candidate IHL-675A. IHL-675A is a combination cannabinoid drug comprising cannabidiol (CBD) and hydroxychloroquine (HCQ) in a fixed dose combination.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/incannex-readying-for-phase-2-clinical-trial-of-anti-inflammatory-drug-ihl-675a-480207835

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  263.04
+3.34 (1.29%)
AAPL  270.17
-0.54 (-0.20%)
AMD  337.11
+13.90 (4.30%)
BAC  52.88
+0.22 (0.42%)
GOOG  347.31
-0.19 (-0.05%)
META  669.12
-2.22 (-0.33%)
MSFT  424.46
-4.79 (-1.12%)
NVDA  209.25
-3.92 (-1.84%)
ORCL  163.83
-2.13 (-1.28%)
TSLA  372.80
-3.22 (-0.86%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.